$2.22 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 91 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 73.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MCK | Buy | MCKESSON CORP | $111,982,000 | +115.8% | 729,000 | +131.1% | 5.04% | +82.2% |
| MYL | Buy | MYLAN N V | $98,929,000 | +86.4% | 3,153,611 | +130.7% | 4.46% | +57.4% |
| GKOS | Buy | GLAUKOS CORP | $83,392,000 | +124.8% | 2,527,032 | +182.5% | 3.76% | +89.8% |
| MNKKQ | Buy | MALLINCKRODT PUB LTD CO | $69,513,000 | +31.6% | 1,860,137 | +57.8% | 3.13% | +11.1% |
| DXCM | Buy | DEXCOM INC | $69,469,000 | +283.2% | 1,419,911 | +472.9% | 3.13% | +223.6% |
| MYOK | Buy | MYOKARDIA INC | $58,492,000 | +1496.0% | 1,365,039 | +387.9% | 2.64% | +1251.3% |
| Buy | ISIS PHARMACEUTICALS INC DELnote 1.000%11/1 | $48,504,000 | +8.0% | 45,700,000 | +8.3% | 2.18% | -8.7% | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $40,726,000 | +300.5% | 1,577,927 | +320.8% | 1.84% | +238.6% |
| Buy | INTERCEPT PHARMACEUTICALS INnote 3.250% 7/0 | $39,674,000 | +80.5% | 51,000,000 | +126.7% | 1.79% | +52.3% | |
| XENT | Buy | INTERSECT ENT INC | $37,692,000 | +13.4% | 1,210,000 | +1.7% | 1.70% | -4.3% |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $36,813,000 | +2.0% | 362,724 | +0.8% | 1.66% | -13.9% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $30,813,000 | +164.6% | 850,000 | +102.6% | 1.39% | +123.5% |
| ANAB | Buy | ANAPTYSBIO INC | $28,811,000 | +117.8% | 824,338 | +49.1% | 1.30% | +83.9% |
| NTRA | New | NATERA INC | $28,120,000 | – | 2,181,542 | +100.0% | 1.27% | – |
| PODD | New | INSULET CORP | $27,375,000 | – | 497,000 | +100.0% | 1.23% | – |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $27,344,000 | +289.0% | 1,072,329 | +157.3% | 1.23% | +228.5% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS | $26,071,000 | +34.0% | 4,975,451 | +42.2% | 1.17% | +13.1% |
| New | K2M GROUP HLDGS INCnote 4.125% 8/1 | $24,498,000 | – | 20,000,000 | +100.0% | 1.10% | – | |
| XLRN | New | ACCELERON PHARMA INC | $22,952,000 | – | 615,000 | +100.0% | 1.03% | – |
| SEM | Buy | SELECT MED HLDGS CORP | $22,936,000 | +196.1% | 1,194,609 | +136.7% | 1.03% | +150.1% |
| PDCO | Buy | PATTERSON COMPANIES INC | $21,876,000 | +18.5% | 566,000 | +43.9% | 0.98% | 0.0% |
| MOH | Buy | MOLINA HEALTHCARE INC | $17,740,000 | +69.1% | 258,000 | +70.1% | 0.80% | +42.7% |
| SYBX | New | SYNLOGIC INC | $16,165,000 | – | 850,143 | +100.0% | 0.73% | – |
| New | AMAG PHARMACEUTICALS INCnote 3.250% 6/0 | $15,747,000 | – | 16,250,000 | +100.0% | 0.71% | – | |
| ARDX | Buy | ARDELYX INC | $15,380,000 | +32.3% | 2,746,480 | +20.5% | 0.69% | +11.8% |
| NEOS | Buy | NEOS THERAPEUTICS INC | $14,356,000 | +34.8% | 1,568,921 | +7.5% | 0.65% | +13.9% |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $13,884,000 | – | 208,000 | +100.0% | 0.62% | – |
| EPZM | Buy | EPIZYME INC | $13,345,000 | +33.4% | 700,526 | +5.8% | 0.60% | +12.5% |
| ALPN | New | ALPINE IMMUNE SCIENCES INC | $10,824,000 | – | 933,100 | +100.0% | 0.49% | – |
| NVTA | New | INVITAE CORP | $8,433,000 | – | 900,000 | +100.0% | 0.38% | – |
| ALIM | Buy | ALIMERA SCIENCES INC | $8,171,000 | +23.2% | 6,052,935 | +26.9% | 0.37% | +4.0% |
| IMMU | New | IMMUNOMEDICS INC | $8,136,000 | – | 582,000 | +100.0% | 0.37% | – |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $7,954,000 | – | 1,355,000 | +100.0% | 0.36% | – |
| CMTA | New | CLEMENTIA PHARMACEUTICALS IN | $7,810,000 | – | 462,387 | +100.0% | 0.35% | – |
| NCNA | New | NUCANA PLCsponsored adr | $7,806,000 | – | 424,950 | +100.0% | 0.35% | – |
| AXGT | Buy | AXOVANT SCIENCES LTD | $7,238,000 | +30.5% | 1,052,000 | +339.8% | 0.33% | +10.1% |
| MCK | New | MCKESSON CORPcall | $6,636,000 | – | 43,200 | +100.0% | 0.30% | – |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $6,172,000 | – | 325,000 | +100.0% | 0.28% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $5,909,000 | – | 190,000 | +100.0% | 0.27% | – |
| AGRX | Buy | AGILE THERAPEUTICS INC | $5,449,000 | +52.1% | 1,221,775 | +27.9% | 0.24% | +28.3% |
| SAGE | New | SAGE THERAPEUTICS INC | $4,236,000 | – | 68,000 | +100.0% | 0.19% | – |
| OBLN | Buy | OBALON THERAPEUTICS INC | $3,348,000 | +84.6% | 351,284 | +91.9% | 0.15% | +55.7% |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $1,864,000 | – | 118,116 | +100.0% | 0.08% | – |
| MDXG | New | MIMEDX GROUP INC | $1,782,000 | – | 150,000 | +100.0% | 0.08% | – |
| RARX | Buy | RA PHARMACEUTICALS INC | $1,491,000 | -3.7% | 102,150 | +23.7% | 0.07% | -19.3% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.